Search results
Results from the WOW.Com Content Network
Global Mapper is a geographic information system (GIS) software package currently developed by Blue Marble Geographics [1] that runs on Microsoft Windows. The GIS software competes with ESRI , GeoMedia , Manifold System , and MapInfo GIS products.
Niacin/lovastatin (trade names Advicor) was a drug combination used for the treatment of dyslipidemia. It was a combination of the lipid-modifying drug/vitamin niacin in extended release form and the statin drug lovastatin (trade name Mevacor). [ 1 ]
Prescription products can be immediate release (Niacor, 500 mg tablets) or extended release (Niaspan, 500 and 1000 mg tablets). Niaspan has a film coating that delays release of the nicotinic acid, resulting in an absorption over a period of 8–12 hours.
Example of a label showing the amount of niacin (Vitamin B3), and specifying to be niacinamide in the ingredient section.. As flour fortification started adding niacin in the US, the United States Government adopted the terms niacin (a shortened form of "nicotinic acid vitamin") and niacinamide in 1942 as alternate names for nicotinic acid and nicotinamide, respectively, and encouraged their ...
Later that same year the product was renamed to Global Mapper and become a commercial product of the company Global Mapper Software LLC. The USGS was distributing a version of the software under the name dlgv32 Pro (Global Mapper). [citation needed] Blue Marble acquired Global Mapper, LLC at the end of 2011. [5]
Acipimox (trade name Olbetam in Europe) is a niacin derivative used as a lipid-lowering agent.It reduces triglyceride levels and increases HDL cholesterol. It may have less marked adverse effects than niacin, although it is unclear whether the recommended dose is as effective as standard doses of niacin.
Liver disease or kidney disease: Niacin can accumulate in people with liver or kidney problems, potentially worsening their condition. [ 1 ] Bleeding disorders : Inositol nicotinate may slow blood clotting, increasing the risk of bleeding for individuals with clotting disorders or those undergoing surgery.
The treatment group received 2 g of extended-release nicotinic acid and 40 mg of laropiprant daily. Study results, reported in July 2014, showed that the combination of nicotinic acid and laropiprant did not have any beneficial effects when compared with a placebo treatment and had an increase in adverse effects.